课题基金 / 基金详情

Critical Role of Inflammatory Macrophages in AAA Pathogenesis

Critical Role of Inflammatory Macrophages in AAA Pathogenesis
炎症巨噬细胞在 AAA 发病机制中的关键作用
批准号:
8312534
负责人:
RONALD L DALMAN
金额:
$23.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-08 至 2014-05-31

项目摘要

项目成果

RONALD L DALMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Abdominal aorta aneurysm (AAA) is a common and lethal disease of adult Americans. Progressive AAA enlargement, over the course of months to years, leads to ever-increasing risk of sudden death from catastrophic rupture. Currently, rupture can only be prevented by timely surgical repair, which carries considerable morbidity and/or requirements for ongoing surveillance and periodic re-intervention. Prior attempts to identify specific mediator or pathway targets for medical intervention have not translated to effective clinical therapies. As the final common effector cell for aneurysmal degeneration, the activated infiltrative macrophage represents a novel and potentially highly effective target for suppression therapy. Surface expression of the folate receptor 2 (FR2) identifies a subset of activated macrophages found to promote various inflammatory conditions including atherosclerosis, arthritis and lupus. Although we have recently confirmed that FR2-positive macrophages are present in significant numbers in experimental aneurysms, the role these cells may play in AAA pathogenesis remains unknown. Based on available supporting information, it is our fundamental hypothesis that FR2-expressing macrophages modulate AAA initiation and progression. To pursue this hypothesis, we propose the following Specific Aims: 1. Quantify the location, timing, and functional correlates of FR2-expressing mural macrophages during AAA disease progression. 2. Define the functional consequences of FR2-expressing macrophage depletion in experimental AAA. Using established and complementary murine models of experimental AAA disease, we will employ immunohistochemical techniques to analyze the kinetics and functional status of FR2-positive macrophages during aneurysm development. We will analyze the functional significance of this subset of activated macrophages by pan- and selected macrophage depletion studies prior to and following initiation of experimental aneurysms. Confirming the pathogenetic significance of activated macrophages in AAA disease will facilitate the rapid translation of emerging anti-FR2 therapeutic strategies to effective non-surgical methods of aneurysm suppression.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/srep11664
发表时间: 2015-07-24
期刊: Scientific reports
影响因子: 4.6
作者: [Fujimura N, Xu B, Dalman J, Deng H, Aoyama K, Dalman RL]
通讯作者: Dalman RL
Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease.
临床和实验性主动脉瘤疾病中缺氧诱导因子1。
DOI: 10.1016/j.jvs.2017.09.030
发表时间: 2018-11
期刊: Journal of vascular surgery
影响因子: 4.3
作者: [Wang W, Xu B, Xuan H, Ge Y, Wang Y, Wang L, Huang J, Fu W, Michie SA, Dalman RL]
通讯作者: Dalman RL
DOI: 10.1161/atvbaha.112.300329
发表时间: 2013-04
期刊: Arteriosclerosis, thrombosis, and vascular biology
影响因子: --
作者: [Iida Y, Xu B, Xuan H, Glover KJ, Tanaka H, Hu X, Fujimura N, Wang W, Schultz JR, Turner CR, Dalman RL]
通讯作者: Dalman RL
DOI: 10.1371/journal.pone.0049642
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者: [Iida Y, Xu B, Schultz GM, Chow V, White JJ, Sulaimon S, Hezi-Yamit A, Peterson SR, Dalman RL]
通讯作者: Dalman RL
The LIMIting AAA with meTformin (LIMIT) Trial
  • 批准号:
    10054902
  • 项目类别:
  • 资助金额:
    $153.25万
  • 财政年份:
    2020
  • 负责人:
    RONALD L DALMAN
  • 依托单位:
The LIMIting AAA with meTformin (LIMIT) Trial
  • 批准号:
    10274809
  • 项目类别:
  • 资助金额:
    $172.93万
  • 财政年份:
    2020
  • 负责人:
    RONALD L DALMAN
  • 依托单位:
The LIMIting AAA with meTformin (LIMIT) Trial
  • 批准号:
    10650132
  • 项目类别:
  • 资助金额:
    $172.82万
  • 财政年份:
    2020
  • 负责人:
    RONALD L DALMAN
  • 依托单位:
Mechanisms and Significance of Angiogenesis in AAA Disease
  • 批准号:
    8228228
  • 项目类别:
  • 资助金额:
    $19.75万
  • 财政年份:
    2012
  • 负责人:
    RONALD L DALMAN
  • 依托单位:
海外基金